Sprint Bioscience is an innovative company that develops small-molecule drug candidates with the potential to become first-in-class, that can fight cancer either individually or in combination with other drugs. Our current attention is immuno-oncology and tumor metabolism. We have established a broad portfolio of preclinical drug projects, three of which have been licensed to international pharmaceutical companies.
Wolfram MathCore develops advanced tools and solutions for modeling and simulation, combining physics-based system models with data-driven approaches such as neural networks. With expertise in Modelica library development, testing, and integration with optimization, probability, and model validation, the company supports industries ranging from energy to mobility. In X-HiDE, Wolfram MathCore contributes with Modelica model libraries for systems biology, methods that merge system models and data models, helping validate and optimize complex processes, and expects to advance hybrid AI-physics workflows for research and industrial applications.
Infla-Med is a Centre of Excellence, established in 2016 at the University of Antwerp, and a recognized leader in preclinical research on inflammation. Bringing together 130 researchers from eight research groups across two faculties, the Centre conducts both fundamental and translational research aimed at identifying new targets and developing innovative therapies and diagnostic tools for inflammatory diseases. Building on a decade of expertise, Infla-Med is honored to support X-HiDE by offering mentorship, sharing knowledge on European grant applications, and fostering the exchange of novel research ideas through joint seminars.
VITROCELL® develops specialized in vitro exposure systems designed to investigate the biological effects of airborne substances, including aerosols, particles, and gases. The systems enable exposures at the air–liquid interface, closely reflecting physiological conditions of the human respiratory tract. They are applied in toxicology, pharmacology, and safety assessment, contributing to the advancement of human-relevant in vitro methodologies and the reduction of animal testing. Within X-HiDE, VITROCELL® will provide expertise on aerosol exposure and its potential to trigger inflammatory responses in the lung, acting as technical advisors to the project. The team will support the integration of advanced exposure technologies into human lung models to enhance the predictive power of in vitro methods for inflammation and hazard identification, while contributing to the development of standardized, reproducible exposure methods.
Mattek, a member of Sartorius, has been a pioneer in the development and implementation of alternative testing methods and 3D human-reconstructed in vitro tissue models from primary cells for over 30 years. The company holds the largest number of international validations, including those from OECD, FDA, ISO, and others. We assist scientists worldwide in accessing cost-effective, highly reproducible, and reliable human-reconstructed tissue models for regulatory and safety assessments. Our models are utilized not only for evaluating chemicals, cosmetics, and household products but also for drug development, wound care, disease research, and metabolic processes.
Glycostem Therapeutics, a clinical-stage biotech company based in the Netherlands, develops innovative allogeneic “off-the-shelf” natural killer (NK) cell therapies that are affordable, accessible, and designed to treat cancer and autoimmune diseases. Our uNiK™ platform enables GMP manufacturing of both unmodified NK products (oNKord®) and genetically engineered NK products (viveNK®, e.g., CAR-NK and TCR-NK), offering safe, scalable, and efficient therapeutic solutions. Building on the strong safety record of our NK cells in two phase I trials, we are now advancing a CAR-NK therapy with promising preclinical results in dual B-cell targeting. This approach, combining CD19 CAR-NK cells with monoclonal antibodies, aims to achieve effective depletion of autoreactive B cells in autoimmune diseases. Through our partnership with the x-Hide consortium, we will access clinical material and expertise to:
test the pre-clinical efficacy of CD19-CAR-NK cells,
identify biosignatures to stratify SLE patients and pinpoint those most likely to benefit from monotherapy or combination approaches, and
design future clinical interventions with CAR-NK cells based on these insights
Genos is the largest and most advanced laboratory dedicated to glycan analysis, setting the standard in high-throughput glycomics research. With the capacity for over 50,000 glycan and glycoproteomic analyses annually, our laboratory handles the majority of global glycan research. Within X-HiDE, our role is to provide state-of-the-art glycan analysis to identify novel biomarkers that can aid in disease prediction, prevention, and patient stratification. We look forward to expanding our collaborative network, sharing expertise, and contributing to the systems-level understanding of inflammation.
